MYE0 Stock Chart & Stats
€0.94
€0.03(3.31%)
At close: 4:00 PM EDT
€0.94
€0.03(3.31%)
Day’s Range― - ―
52-Week Range€0.56 - €1.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€131.40M
Enterprise Value€42.95M
Total Cash (Recent Filing)€105.69M
Total Debt (Recent Filing)€17.25M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Nov 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding103,206,210
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.56Price Target Upside279.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.25
Revenue Forecast (FY)€28.66M
Bulls Say, Bears Say
Bulls Say
Genentech PartnershipThe Genentech enterprise agreement broadens MaxCyte’s role across research, clinical development, and commercial manufacturing workflows. Earlier customer engagement can expand platform adoption, create more monetization points, and strengthen the company’s strategic position beyond individual therapeutic programs.
Balance Sheet StrengthA substantial cash balance combined with no debt gives MaxCyte financial flexibility while it develops its platform and manages continued losses. This reduces refinancing pressure, supports ongoing investment in strategic programs, and provides a meaningful buffer against uneven partner revenue.
Cost DisciplineThe sharp reduction in operating expenses improves the company’s ability to control cash consumption while preserving strategic R&D investment. If the lower cost base holds as revenue stabilizes or grows, MaxCyte could gain operating leverage and narrow losses over future periods.
Bears Say
Revenue ContractionDeclining total and core revenue indicate that platform demand has not yet translated into consistent near-term growth. Continued weakness in the core business could limit operating leverage, reduce recurring consumables and services pull-through, and make the revenue outlook more dependent on partner programs.
Persistent Losses And Cash BurnPersistent accounting losses and negative operating and free cash flow show that MaxCyte is still funding operations rather than self-financing. Although liquidity is strong, continued burn can consume capital over time and constrain the company’s ability to invest without relying on its existing cash reserves.
Gross Margin PressureThe lower gross margin reflects a product mix with a greater proportion of lower-margin instruments and suggests that strong historical platform economics may not fully translate into near-term profitability. Sustained mid-70s margins would leave operating expenses difficult to cover while revenue remains soft.
MaxCyte News
MYE0 FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was €0.56 and its highest was €1.48 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is €131.40M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on Aug 12, 2026. The company reported -€0.071 earnings per share for the quarter, beating the consensus estimate of -€0.08 by €0.009.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.07.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 103,206,210 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -€0.071 in its last earnings report, beating expectations of -€0.08. Following the earnings report the stock price went down -17.544%.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in DE:MYE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.56 (279.06% Upside)
€3.56 (279.06% Upside)
Blogger Sentiment
Neutral
DE:MYE0 Sentiment 50%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.03%
12-Months-Change
Fundamentals
Return on Equity
-21.01%
Trailing 12-Months
Asset Growth
-15.96%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MYE0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company that has stabilized near-term revenue, materially reduced operating expenses, and strengthened its strategic positioning through a large enterprise partnership (Genentech), while maintaining a strong balance sheet. These positives were offset by notable year-over-year revenue declines, gross margin pressure due to product mix, and prior partner/program headwinds. Management reiterated guidance and expects a return to growth in H2 2026, with further upside tied to SPL royalties and instrument adoption.View all DE:MYE0 earnings summariesMYE0 Stock 12 Month Forecast
Average Price Target
€3.56
▲(279.06% Upside)